title: [Continuing progress in withdrawal of axillary dissection in early stage breast cancer].
abstract: For a long period of time, axillary dissection represented a standard approach for axillary node management in the case of sentinel node biopsy positivity during early stage breast cancer treatment. In recent years, there has been a trend to highlight the morbidity of such an axillary procedure considering longterm survival of early stage breast cancer patients. Two big trials, AMAROS and Z0011, were initiated to answer the question whether axillary dissection should be performed in the case of positivity of axillary sentinel node considering the fact that more than 70% of these patients will have no metastasis found during the axillary dissection and such a procedure only increases the morbidity of the surgery. Considering the results of the above mentioned trials, axillary dissection may be avoided in the case of fulfilling of inclusion criteria of these trials without any impact on the patient survival. IBCSG 23- 01 study brought similar conclusion in the case of micrometastasis in axillary sentinel node.
authors.forename: D
authors.initials: D
authors.lastname: Vrána
authors.forename: J
authors.initials: J
authors.lastname: Gatěk
authors.forename: K
authors.initials: K
authors.lastname: Cwiertka
authors.forename: V
authors.initials: V
authors.lastname: Srámek
mesh_terms: D001365:Axilla; D001943:Breast Neoplasms / Q000473:pathology*; D005260:Female; D006801:Humans; D008197:Lymph Node Excision; D008198:Lymph Nodes / Q000473:pathology*; D008207:Lymphatic Metastasis; D061206:Neoplasm Micrometastasis / Q000473:pathology*; D021701:Sentinel Lymph Node Biopsy; D019564:Unnecessary Procedures